The PGspot - The Pink Pill Paradox: Sex, Science, and Double Standards

When it comes to sexual health treatments, why have men historically had more options than women? In this episode of The PG Spot, Dr. Patty Jalomo explores the fascinating and controversial journey of Addyi (flibanserin), the first FDA-approved medication for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.

We'll dive into the years-long approval process, the advocacy movement that challenged the FDA, and the debates surrounding safety, efficacy, and gender equity in medicine. Along the way, we'll examine a larger question: Why has women's sexual health research lagged behind men's, and how has that affected treatment options for low desire and sexual dysfunction?

Whether you're a healthcare professional, a woman struggling with low desire, or simply curious about the intersection of science, policy, and sexual health, this episode sheds light on the ongoing effort to close the gap in sexual medicine and ensure that women's sexual well-being receives the attention it deserves.

Join us as we explore the story behind the "little pink pill" and what it reveals about the future of women's sexual health.

If you want to learn more about sexual health, sexual dysfunction, or how to improve your sex life, follow me on Instagram at @thepgspot or check out my website at doctorpattyj.com for blogs and resources related to sex positivity and real talk about sexuality.  As as always, stay curious, stay empowered, and stay you.

Transcript

0:08

Welcome to The PG Spot, where our goal is to take the ex out of sex by breaking down the barriers that prevent open communication about sexual health. I'm Dr. Patty Jalomo, a dual-certified nurse practitioner, pelvic floor therapist, and certified sexual counselor. I'm here to provide expert insights, debunk myths, and empower you to embrace your sexual well-being. Whether you're looking for answers or simply curious, join us as we open up the conversation around sex, intimacy, and everything in between. I want to take this opportunity to acknowledge that some content may not be appropriate for all listeners. I'm a huge proponent of honest and accurate information regarding sexuality, but I'm also mindful that this should be age-appropriate. Therefore, if you are under 18, this may not be the podcast for you. Additionally, some of the language used in this podcast may be offensive to some listeners. Please take these things into consideration before going forward with your consensual participation in this podcast. The opinions expressed by myself or my guests are just that, and these opinions are neither expected nor required to be shared by all listeners. The information that is provided is for educational and entertainment purposes only and should not be mistaken for individual medical advice. If you would like to schedule a virtual visit for individual or couples sexual counseling or menopause management, you can contact me via my website at thepgspot.com. Thanks for listening, and let's get on with the show Hey everyone, welcome back to The PG Spot. I'm your host, Dr. Patty Jalomo, and today we're diving into a fascinating story that sits at the intersection of medicine, gender, politics, and sexuality. Let me start with a few questions. Have you ever wondered why most people can name at least one medication for erectile dysfunction, but very few people can name a medication designed to treat low sexual desire in women? And did you know that the first medication approved for low sexual desire in women took nearly two decades to reach the market, while medications for erectile dysfunction became household names almost overnight? For decades, pharmaceutical companies invested heavily in treatments for male sexual dysfunction. Medications like Viagra became household names almost overnight, changing the conversation around erectile dysfunction and creating an entirely new market for men's sexual health treatments. Meanwhile, women experiencing sexual concerns, particularly low sexual desire, had few medical options available. In fact, it wasn't until 2015 that the FDA approved the first medication specifically indicated for hypoactive sexual desire disorder, or HSDD, in premenopausal women. That medication was flibanserin, marketed under the brand name Addyi. But the story of Addyi is about much more than a single medication. Its path to approval was long, controversial, and filled with debate. Some argued that women were being held to a different standard than men when it came to sexual health treatments. Others maintained that the FDA's concerns were based on legitimate questions about safety and effectiveness. So today we're going to unpack the history behind Flibanserin, explore the differences between male and female sexual dysfunction treatments, and examine a larger question that continues to influence healthcare today. When it comes to sexual medicine, have men and women truly been treated equally? So let's get into it Before we can understand why the approval of flibanserin generated so much discussion, it's important to recognize that sexual dysfunction is not exclusively a men's health issue. When people think about sexual dysfunction, erectile dysfunction is often the first condition that comes to mind. It's widely discussed in advertisements, television commercials, and other popular culture. Most adults have heard of erectile dysfunction and know that treatments are available. But sexual dysfunction can affect people of all genders, and in women, it can present in several different ways. Some women experience difficulty with sexual desire, meaning they have little or no interest in sexual activity. Others may have difficulty becoming aroused, reaching orgasm, or may experience pain during sexual activity. These concerns can be temporary or long-term, and they can be influenced by a wide range of factors, including hormones, medications, medical conditions, mental health, stress, relationship dynamics, and life circumstances. One condition that has received particular attention is hypoactive sexual desire disorder, often abbreviated as HSDD. HSDD is characterized by a persistent lack of sexual desire that causes personal distress, and that last part is important. Having a low sex drive is not automatically a medical problem. People have different levels of sexual desire, and those differences are completely normal. The concern arises when a loss of sexual desire is unwanted and causes significant distress. And that's an important thing to remember throughout today's episode because as we get into discussions about research, regulations, and treatment options, it's easy to lose sight of the fact that we're talking about real people whose quality of life may be affected by these conditions For many years, women's sexual concerns were often minimized, misunderstood, or attributed solely to psychological causes. While emotional and relationship factors can absolutely influence sexual function, researchers have increasingly recognized that female sexual desire is influenced by a complex interaction of biological, psychological, and social factors. The impact can be substantial. Sexual dysfunction may affect self-esteem, intimate relationships, emotional well-being, and overall quality of life. Yet, despite how common these concerns are, research into female sexual health has historically lagged behind research focused on male sexual function. Now, for many of you that have listened to some of my previous episodes, this is not a surprise. There are many examples of disparities women face when it comes to medical research. Testosterone is just one that comes to mind, probably because it's a hot topic in the world of menopause management and female sexual function. but this disparity raises an important question. If sexual dysfunction affects both men and women, why have treatment options developed so differently? To answer that question, we need to go back to the late 1990s and the arrival of a little blue pill that would completely change the landscape of sexual medicine To understand why flibanserin's approval became such a lightning rod for debate, we first need to talk about Viagra. In the early 1990s, researchers were studying a medication called sildenafil as a potential treatment for cardiovascular conditions such as angina or chest pain caused by reduced blood flow to the heart. While the drug wasn't particularly successful for its original purpose, researchers noticed an unexpected side effect among study participants, and that was improved erections. What might have been considered an inconvenience in another clinical trial turned out to be a groundbreaking discovery and one that makes perfect sense. The primary supposed mechanism of action of sildenafil was to improve blood flow to the heart. And what does a penis need to become erect? Blood flow. So it stands to reason that sildenafil works by increasing blood flow to the penis, helping men achieve and maintain an erection when sexually stimulated. Once researchers recognized sildenafil's potential as a treatment for erectile dysfunction, the drug moved from an unexpected side effect to FDA approval in just a few years. By 1998, Viagra had reached the market and quickly became one of the most recognizable prescription medications in the world. Television commercials, magazine advertisements, and celebrity endorsements helped bring conversations about erectile dysfunction into the mainstream. A condition that many men had previously suffered through in silence was suddenly being discussed openly as a legitimate medical issue With an available treatment. The success of Viagra also signaled something important to the pharmaceutical industry. Men's sexual health treatments could be both medically meaningful and commercially successful. In the years that followed, additional medications for erectile dysfunction entered the market, including Tadalafil, better known by the brand name Cialis, and Vardenafil, marketed as Levitra. Men now had multiple treatment options available for a condition that affected their sexual health and quality of life. For many advocates of women's sexual health, this rapid expansion of treatment options highlighted a striking contrast While erectile dysfunction was receiving significant research funding, public attention, and pharmaceutical innovation, women experiencing sexual concerns had few FDA-approved treatment options available. some questioned why male sexual dysfunction appeared to be a priority while female sexual dysfunction remained understudied and underfunded. Now, some might argue that they are completely different issues, which technically is correct. Although erectile dysfunction and low sexual desire are often discussed together, they are fundamentally different conditions. erectile dysfunction is primarily a problem involving blood flow and the physical ability to achieve an erection. Hypoactive sexual desire disorder, on the other hand, involves complex interactions between the brain, hormones, emotions, relationships, and overall health. In other words, researchers weren't looking for a female version of Viagra because female sexual desire doesn't work the same way an erection does. But that doesn't make the issue less important or less impactful to one's quality of life. Many people believe that women deserve the same level of scientific attention and investment that had transformed treatment options for men And that brings us to flibanserin, a medication that would spend years navigating clinical trials, FDA reviews, public controversy, and accusations of gender bias before finally becoming the first approved treatment for low sexual desire in women The story of Flibanserin begins much like the story of Viagra, With a medication that was originally intended for something else entirely Researchers hoped it would help treat mood disorders by affecting neurotransmitters in the brain, including serotonin, dopamine, and norepinephrine. During clinical trials, however, the medication did not demonstrate enough benefit to move forward as an antidepressant. But researchers noticed something interesting. Some women taking the medication reported increases in sexual desire. Rather than abandoning the drug altogether, investigators began exploring whether it could be used to treat hypoactive sexual desire disorder, or HSDD, in premenopausal women. At first, this seemed promising. Here was a potential treatment for a condition that affected millions of women and for which there was no FDA-approved medications available. However, unlike Viagra, which primarily works by improving blood flow, flibanserin acts on neurotransmitters within the brain. Researchers believed it might help restore balance among chemical pathways involved in sexual desire, but the exact mechanism is not fully understood. As clinical trials progressed, the results generated both excitement and controversy. Some studies showed that women taking flibanserin experienced modest improvements in measures of sexual desire and reported more satisfying sexual events compared to those taking a placebo. However, the improvements were relatively small, leading some experts to question whether the benefits were clinically meaningful At the same time, concerns emerged regarding side effects. Some women taking flibanserin reported adverse effects including dizziness, fatigue, nausea, and sleepiness. Researchers also identified risks of low blood pressure and fainting, particularly when the medication was combined with alcohol. These concerns became central to the FDA's review process In 2010, the FDA declined to appl- In 2010, the FDA declined to approve flibanserin, citing concerns about both efficacy and safety. The clinical trials showed that women taking flibanserin experienced about one half to one additional satisfying sexual event per month compared with women taking a placebo. Supporters argued that even modest improvements could be meaningful for women experiencing significant distress. Critics, however, questioned whether that level of benefit justified the medication's risks and side effects. So additional studies were conducted, and the manufacturer resubmitted the application. In 2013, the FDA again rejected the drug, requesting further evidence that the benefits outweighed the risks By this point, the discussion had expanded beyond the scientific data. According to the documentary, The Little Pink Pill, concerns were raised during the review process about whether the medication's sedating effects could impair activities such as driving the next day. Some advocates took issue not only with the concern itself, but also with the example being used. They argued that references to women driving their children to school reflected broader societal assumptions about women's roles and contributed to a tendency to view women's sexual health through a different lens than men's. Advocacy groups began questioning whether women were being treated fairly when it came to sexual health treatments. one campaign known as Even the Score, argued that there was a significant imbalance between the number of treatment options available for men and those available for women. Supporters pointed out that numerous medications had been approved to address aspects of male sexual dysfunction, while women still had no FDA-approved medication specifically for low sexual desire. The campaign attracted national attention and sparked conversations around gender equity in medicine, research funding, and regulatory decision-making. Critics, however, pushed back against the idea that the issue was solely about gender. Some argued that the FDA was appropriately evaluating the available evidence and that approval decisions should be based on safety and effectiveness, regardless of whether the medication was intended for men or women. In 2015, after additional studies and extensive review, the FDA finally approved Flibanserin under the brand name Addyi for the treatment of acquired generalized hypoactive sexual desire disorder in premenopausal women. However, the approval came with important restrictions. Because of concerns regarding severe hypotension and syncope, especially when combined with alcohol, the medication initially carried a boxed warning and was subject to a risk evaluation and mitigation strategy, or REMS program. The REMS requirement meant that prescribers had to be specially certified, pharmacies had to be certified, and patients had to be counseled about risks, particularly the risk of severe low blood pressure and fainting, especially when alcohol was involved. From the beginning, this restriction was controversial. Some clinicians and advocates argued that the safety concerns, while real, were being managed in a way that created unnecessary barriers to access, especially given that patients were already being prescribed other medications with significantly higher risk profiles under far less restrictive systems. Over time, additional data began to emerge from post-marketing experience and clinical studies, including information suggesting that the risk of severe hypotension and syncope was lower than initially feared when the medication was used as directed. There was also growing discussion about whether alcohol restrictions and prescriber certification requirements were proportionate to the actual risks seen in practice. Sprout Pharmaceuticals and later Bosch Health supported efforts to revisit the REMS requirements, presenting updated safety data to the FDA and arguing that the restrictions were limiting patient access without providing a meaningful additional safety benefit In 2023, the FDA ultimately modified the REMS program for Addyi, removing some of the most restrictive elements. While the medication still carries warnings, particularly regarding alcohol use, the prescriber certification and pharmacy certification requirements were eliminated, making it significantly easier for clinicians to prescribe This change represented an important regulatory shift. It didn't mean that the risks disappeared, but it did reflect how the FDA can adjust its requirements over time as more real-world data becomes available. For many advocates, this was seen as a partial validation of their long-standing argument that the initial barriers to access may have been more restrictive than necessary. For regulators, it reflected a more typical life cycle of medication oversight, starting cautiously and then recalibrating as evidence accumulates. But the story didn't end with FDA approval. In fact, one of the most surprising chapters was just beginning Only two days after the FDA approved Addyi in August 2015, Sprout Pharmaceuticals, the small North Carolina company that had spent years fighting for the drug's approval, was acquired by pharmaceutical giant Valeant Pharmaceuticals in a deal valued at approximately one billion dollars. The timing was remarkable. After years of clinical trials, regulatory reviews, and public debate, Sprout's founders had finally achieved approval for the first medication indicated for HSDD in premenopausal women, and almost immediately the company changed hands. many expected that a large pharmaceutical company with extensive resources would be able to successfully market Addyi and expand access to the medication. But things did not go as planned. Addyi's sales fell short of expectations. Questions about the drug's effectiveness, concerns regarding side effects, restrictions associated with the REMS program, and challenges with insurance coverage all created obstacles to widespread adoption. As sales struggled, disagreements emerged between Valeant and former Sprout shareholders regarding the company's obligations to support and market the drug. Litigation followed, with former investors alleging that Valeant had failed to meet certain commitments related to commercialization efforts. Then came an unexpected twist. In twenty seventeen, just two years after purchasing Sprout for roughly one billion dollars, Valeant agreed to sell the company back to an entity affiliated with its former owners. Under the agreement, Valeant would receive a small royalty on future Addyi sales and provide a twenty-five million dollar loan to help fund operations. In other words, the company that had fought to bring Addyi to market ultimately regained control of the product that it created. At the center of this story was Sprout co-founder and CEO, Cindy Whitehead, who became one of the most recognizable advocates for women's sexual health. To supporters, she represented a determined entrepreneur who challenged a system that had historically invested more heavily in male sexual health treatments. To critics, she was a controversial figure, with some arguing that the marketing around the drug moved faster than the strength of the scientific evidence. Regardless of where one stands on the debate, the Addyi story is unique. Few drugs have traveled such a winding path from failed antidepressant to controversial FDA approval to a billion-dollar acquisition, and then back into the hands of the very company that fought to bring it to the patients in the first place. For some, the approval represented a major milestone in women's sexual health. For others, it remained an example of a medication whose benefits may not clearly outweigh its risks. What everyone could agree on was this, the debate surrounding flibanserin had become about much more than a single drug. It had evolved into a larger conversation about how society, researchers, pharmaceutical companies, and regulators view women's sexual health. And that raises an important question, Was the controversy truly evidence of gender inequality in medicine, or were there legitimate scientific reasons for the differences between Flibanserin and drugs like Viagra? And it also brings up another question, was the lengthy approval process for flibanserin evidence of gender bias in medicine, or was the FDA simply doing its job? Supporters of flibanserin's approval pointed out that by 2015, there were multiple FDA-approved medications available to help men with erectile dysfunction. These treatments had become widely accepted, heavily marketed, and relatively easy to access. meanwhile, women experiencing distressing sexual concerns had no FDA-approved medication specifically indicated for low sexual desire. Advocates argued that this disparity reflected a broader pattern within healthcare. Historically, women have often been underrepresented in clinical research, and conditions that primarily affect women have sometimes received less funding and scientific attention. Critics of the FDA's decision questioned whether women's sexual wellbeing was being taken as seriously as men's. Some also argued that society tends to view male sexual function as an important component of overall health, while dismissing women's sexual concerns as less urgent or less deserving of treatment. Another important consideration is the significant time and money spent on getting FDA approval. Sildenafil reached FDA approval within a few years of the shift of focus, whereas Flibanserin underwent multiple FDA rejections over roughly five years after it was repurposed from an antidepressant, twenty ten, twenty thirteen, and then finally was approved in twenty fifteen. This is a hard fact for supporters to overlook. From this perspective, the struggle to get flibanserin approved symbolized a larger issue. Women's sexual health had simply not been prioritized to the same extent as men's. But there is another side to the argument. Critics of flibanserin's approval argued that the FDA's concerns were not about gender, but about the available evidence. They pointed to the medication's modest effectiveness and potential safety risks, including low blood pressure, fainting, and interactions with alcohol. From their perspective, the FDA was applying the same standard it should apply to any medication. Do the benefits outweigh the risks? many experts emphasize that comparing Viagra and flibanserin may not be entirely fair because they treat fundamentally different conditions. Viagra works on the vascular system, helping to increase blood flow to the penis. Its effects are relatively predictable and measurable. Flibanserin, on the other hand, affects neurotransmitters in the brain and aims to influence sexual desire itself, a much more complex and difficult outcome to measure. The flibanserin story does not fit neatly into a simple narrative of right versus wrong. It is possible that the FDA had valid concerns about safety and efficacy. At the same time, it's also possible that historical biases in medicine may have influenced how those risks were interpreted or emphasized in this case. And then there's the fact that historical under-investment in women's sexual health had contributed to the lack of treatment options available in the first place The scientific challenges of studying female sexual desire are real. So are the historical disparities in research funding, public attention, and pharmaceutical development focused on women's sexual health. What makes this story so fascinating is that it forces us to examine how medicine decides which conditions deserve attention, which symptoms are considered worthy of treatment, and whose experiences are prioritized when resources are limited. Whether you view flibanserin as a victory for women's health, a controversial approval, or something in between, its journey brought national attention to a topic that has been overlooked. Women's sexual wellbeing matters, and it deserves serious scientific study. The question now is: where do we go from here? More than a decade after Addyi's approval, the conversation surrounding women's sexual health continues to evolve While flibanserin was the first FDA-approved medication for HSDD in premenopausal women, it is no longer the only option available. In 2019, the FDA approved bremelanotide, marketed as Vyleesi, another treatment for acquired generalized HSDD in premenopausal women. Unlike Addyi, which is taken daily, Vyleesi is administered as an injection before anticipated sexual activity. Unfortunately, these medications are still cost-prohibitive, which makes it difficult as a provider to offer these prescriptions to patients While the approval of these medications represent progress, it also highlights an important reality. There is no one-size-fits-all solution for sexual dysfunction. Sexual desire is influenced by a complex combination of biological, psychological, relational, and social factors. Hormonal changes, chronic health conditions, medications, stress, anxiety, depression, relationship challenges, and life circumstances can all affect a person's interest in sex. Because of this complexity, treatment often involves much more than just medication alone. Healthcare providers may recommend counseling, sex therapy, treatment of underlying medical conditions, medication adjustments, stress management strategies, or relationship-focused interventions. For some individuals, these approaches may be more effective than the medication. For others, a combination of therapies may provide the best results. At the same time, researchers continue to explore female sexual health in ways that were uncommon just a few decades ago. There is a growing recognition that sexual well-being is not simply a luxury or an optional aspect of health. It can have meaningful effects on quality of life, emotional wellness, relationships, and overall health. Yet challenges remain. Many women still report feeling uncomfortable discussing sexual concerns with healthcare providers. Some clinicians receive limited training in sexual medicine. Research funding for female sexual health continues to lag behind funding in other areas, and many questions about the causes and treatment of sexual dysfunction remain unanswered. The good news is that conversations that were once considered taboo are becoming more common. Patients are asking questions. Researchers are studying these conditions more closely. healthcare providers are becoming increasingly aware of the importance of sexual health as part of comprehensive patient care. And perhaps that is one of the most significant outcomes of the Flibanserin story. Whether you believe Addyi was long overdue, approved too cautiously, or approved despite ongoing concerns, its journey forced healthcare professionals, regulators, researchers, and the public to acknowledge something important. Women's sexual health deserves attention, research, and evidence-based treatment options. The conversation is far from over, but it is moving forward, and that's exactly where progress begins. As we wrap up today's episode, let's go back to the questions that we started with. Why was there a Viagra long before there was an FDA-approved medication for low sexual desire in women? And maybe more importantly, if male and female sexual dysfunction are both legitimate medical concerns, what does equitable treatment really look like? The story of Flibanserin is about more than one medication. It raises important questions about whose symptoms get studied, whose concerns are prioritized, and how society defines sexual health As you've probably realized by now, there isn't a simple answer. Part of the story involves biology. Erectile dysfunction and hypoactive sexual desire disorder are fundamentally different conditions, and developing treatments for sexual desire is far more complex than just improving blood flow. Part of the story involves safety, efficacy, and the rigorous standards that all medications must meet before receiving FDA approval. But part of the story may also involve how we as a society have historically viewed sexual health. Whose symptoms are taken seriously? Which conditions receive research funding? What aspects of sexual well-being are considered worthy of medical attention? And who gets a seat at the table when those decisions are made? The journey of flibanserin reminds us that medicine does not exist in a vacuum. Scientific research, healthcare policy, cultural attitudes, and patient advocacy all influence the treatments that ultimately become available. Whether you see Addyi as a breakthrough for women's sexual health, a controversial approval, or something in between, its story sparked an important conversation, one that continues today. It challenged researchers, healthcare providers, regulators, and patients to think more critically about equity in sexual medicine and the importance of addressing sexual health concerns for everyone. And perhaps that's the biggest takeaway from today's discussion. Sexual health is health. It deserves the same attention, research, and evidence-based care as any other aspect of physical or emotional well-being. Thank you for joining me for this episode, and be sure to join me next time as we explore another topic where medicine, public policy, and personal choice intersect. That's it for today's episode. Thanks for listening, and be sure to rate and review the podcast on whatever platform you're listening from, and share it with your friends. That's a great way to help reach new listeners and make this a more sex-positive world. Until next time, stay curious, stay empowered, and stay you.